NB-303

N/A

Report date: 2024/01/19 16:29:33

Base Information

Drug NameNB-303
Drug Alias NameNB-303NB303
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionT lymphocytes stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNeoLogics Bioscience Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeoLogics Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A